Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
4DMedical Ltd ( (AU:4DX) ) has provided an announcement.
4DMedical Limited reported a significant increase in operating revenue for the year-to-date FY2025, achieving a 103% rise compared to the previous period, with gross margins of 91.4%. The company is expanding its sales pipeline and has secured key contracts, including a renewal with the Cleveland Clinic and conversions of pilot programs into commercial contracts. A cost reduction program has been implemented, resulting in $6.5 million in annualized savings. The company is preparing for the FDA submission of its CT:VQ™ product, which has attracted interest from major medical centers and industry collaborators. Additionally, 4DMedical has received regulatory clearance for its CT LVAS™ in Canada and has been highlighted by Philips as a solution for improving veteran health outcomes.
More about 4DMedical Ltd
4DMedical Limited is a company specializing in respiratory imaging technology, focusing on providing innovative solutions for lung health. The company offers Software-as-a-Service (SaaS) products and has a significant presence in both the U.S. and Australian markets, with a growing global footprint.
YTD Price Performance: -41.67%
Average Trading Volume: 955,430
Technical Sentiment Signal: Buy
Current Market Cap: A$126.2M
See more data about 4DX stock on TipRanks’ Stock Analysis page.